{"id":6452,"date":"2023-05-09T11:00:00","date_gmt":"2023-05-09T02:00:00","guid":{"rendered":"https:\/\/hbio.jp\/news\/?p=6452"},"modified":"2024-08-23T19:30:45","modified_gmt":"2024-08-23T10:30:45","slug":"cancer-test-for-dogs-n-nose-plus-dogs-service-launch-from-tuesday-may-9","status":"publish","type":"post","link":"https:\/\/hbio.jp\/news\/en\/2023\/05\/09\/cancer-test-for-dogs-n-nose-plus-dogs-service-launch-from-tuesday-may-9\/","title":{"rendered":"Cancer Test for Dogs \u201cN-NOSE plus Dogs\u201d Service Launch from Tuesday, May 9"},"content":{"rendered":"\n

HIROTSU BIO SCIENCE INC. (Head Office: Chiyoda-ku, Tokyo; Representative; Takaaki Hirotsu (Hereinafter referred to as \u201cHIROTSU\u201d)), is pleased to announce that the test kit shipments for the canine cancer test \u201cN-NOSE plus Dogs\u201d will begin on Tuesday, May 9, and we will provide the \u201cOwner and Dog Pair Test.\u201d<\/strong><\/p>\n\n\n\n

\"2023_05_09<\/figure>\n\n\n\n

The cancer incidence rate in dogs is said to be eight times higher than in humans, and cancer is the leading cause of death among dogs (*1). Since dogs cannot report pain or discomfort themselves, it is often the case that the illness has progressed by the time the owner notices something is wrong. In a landscape where convenient cancer screenings for dogs are almost non-existent, we have fully committed to developing a nematode-based cancer test for dogs, driven by our desire to protect canine health. After approximately five years of joint research with partner institutions, we are now ready to offer this service (*2).<\/p>\n\n\n\n

\u201cN-NOSE plus Dogs\u201d is a primary screening test for assessing cancer risk in dogs, developed by applying the technology of the nematode cancer test \u201cN-NOSE,\u201d which has surpassed a cumulative total of 400,000 users (*3). By simply submitting a urine sample, owners can check for risks of various cancers commonly found in dogs, such as lymphoma, mammary gland cancer, and skin cancer (*4). Following a reservation period starting on March 10, we will now begin shipping test kits and conducting tests. Additionally, we will offer the service of the \u201cOwner and Dog Pair Test\u201d to ensure a healthy future for both owners and their dogs, providing a cost-effective option. Should the test indicate a high risk, we will provide free aftercare services, including guidance from veterinarians on the next steps and information about partner animal hospitals, to support a process that leads to early detection.<\/p>\n\n\n\n

Overview of \u201cN-NOSE plus Dogs\u201d<\/span><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n


Start Date: Tuesday, May 9, 2023
How to Apply for Service: Service website, and partner animal hospitals (starting from early June)
Test Fee:
Regular Testing: \u00a516,800 (including tax) per test (choose from once a year, twice a year, or three times a year)
One-Time Test: \u00a519,800 (including tax)
\u201cOwner and Dog Pair Test\u201d Discount (applicable for up to 5 family members of the owner and up to 5 dogs):
Regular Testing: \u00a52,000 discount per kit
One-Time Test: \u00a51,000 discount per kit
Service Website:\u00a0https:\/\/lp.n-nose.com\/dog\/<\/a><\/p>\n\n\n\n

(*1) Dog cancer incidence rate: Calculated from the figures in \u201cAnicom Household Pet White Paper 2022\u201d for dogs over 6 years old, cancer incidence rates in people over 40 from \u201cNational Cancer Registry\u201d 2019 data and \u201cMinistry of Health, Labour and Welfare Vital Statistics\u201d 2019 data. Dog mortality data: \u201cAnicom Household Pet White Paper 2021\u201d for dogs over 10 years old.
(*2) Results of Collaborative Research:
[Paper]
December 2022: \u201cA new detection method for canine and feline cancer using the olfactory system of nematodes\u201d (Biochemistry and Biophysics Reports)
[Conference Presentations]
(*3) As of the end of April 2023
(*4) Liver cancer, mammary gland cancer, lymphoma, thyroid cancer, multiple myeloma, sarcoma, bone tumor, urothelial cancer, brain tumor<\/p>\n\n\n\n

Download PDF<\/a>
<\/p>\n","protected":false},"excerpt":{"rendered":"

HIROTSU BIO SCIENCE INC. (Head Office: Chiyoda-ku, Tokyo; Representative; Takaaki Hirotsu (Hereinafter referre […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_locale":"en_US","_original_post":"https:\/\/hbio.jp\/news\/?p=6452","footnotes":""},"categories":[3],"tags":[],"class_list":["post-6452","post","type-post","status-publish","format-standard","hentry","category-press-release","en-US"],"acf":[],"_links":{"self":[{"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/posts\/6452","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/comments?post=6452"}],"version-history":[{"count":4,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/posts\/6452\/revisions"}],"predecessor-version":[{"id":6481,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/posts\/6452\/revisions\/6481"}],"wp:attachment":[{"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/media?parent=6452"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/categories?post=6452"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/tags?post=6452"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}